Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. - Wikidata - wikimedia - TriplyDB

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

http://www.wikidata.org/entity/Q51984024

about

Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia Human recombinant activated protein C for severe sepsis Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients Human recombinant activated protein C for severe sepsis Human recombinant activated protein C for severe sepsis Polyphosphate and omptins: novel bacterial procoagulant agents Coagulation in sepsis: all bugs bite equally Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.Pancreatic injury in patients with septic shock: A literature review Sepsis and disseminated intravascular coagulation Inflammation and haemostasis The coagulopathy of acute sepsis Host innate immune responses to sepsis Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis Coagulation abnormalities in critically ill patients Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans Hyperresponsiveness of mice deficient in plasma-secreted sphingomyelinase reveals its pivotal role in early phase of host response Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis Practical aspects of treatment with drotrecogin alfa (activated)Hemostatic abnormalities in critically ill patients.Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study Another step in improving the diagnosis of disseminated intravascular coagulation in sepsis.A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis.New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study.The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients Disseminated intravascular coagulation: a review for the internist.Mortality predictors in renal transplant recipients with severe sepsis and septic shock.Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia.Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction.Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock.Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.The efficacy and safety of different anticoagulants on patients with severe sepsis and derangement of coagulation: a protocol for network meta-analysis of randomised controlled trials.Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.Histones Induce the Procoagulant Phenotype of Endothelial Cells through Tissue Factor Up-Regulation and Thrombomodulin Down-Regulation.Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis

P2860

Q21194921-84A40C57-5180-48BA-A76C-F01BA873B063 Q24201123-5EFE9737-CFC2-47C6-B063-73B8BA15C273 Q24202128-A9B2E469-DA9A-412B-8FF4-1435996CA627 Q24235181-1C83A9E0-64A2-4D10-84A0-CF60AAF0796F Q24242859-F06D873F-2E9E-4480-96E1-DF2800E323D9 Q24629548-2086778D-38E0-41D5-A97B-940E67D07F37 Q24805503-EB64E786-35B5-4F13-B2C3-8FE5ADB8DB83 Q24810495-726D2F5F-10B8-4681-946A-3C2F09166F9E Q26738929-B61A6748-B930-482F-8A52-81AAFF5F5F6E Q26751555-635F3114-4F12-4CB0-A3AC-94C43C48AB99 Q26823258-41AEE74A-5B67-46F4-A693-23C6ABE7CA70 Q26826950-02F41F54-05B8-4D84-A2A4-A619769F685A Q26864635-98D0F550-E1DE-4648-9809-846074EC21E2 Q28076449-CE446CB6-ADE3-4310-B5F3-C52B0AC98DA9 Q28199912-0CE91DEF-E95F-4A81-955C-A2DBC89A5968 Q28296136-710E504A-318E-4F91-BFFF-447BA2B82524 Q30531999-B307F1DF-E7A5-40EB-B534-F4898A02CC32 Q33288889-D9DB9AE4-EF35-4E31-98C4-9C8B2BBBD220 Q33378616-C6B8DAE9-2000-4A58-AC4D-50534C206BD2 Q33419474-142BCA4D-4BA4-4468-B3E4-3841BB6CDF87 Q33426245-70E13EC8-689C-4E7C-86CC-4C580ADF741E Q33712746-E55E3AF8-181E-4B3C-8C15-CA9A119FF28F Q33750809-F184B1BF-5CAD-448C-BAB1-7DC6FBA9A80E Q33752101-A7DBC9E7-0ED5-4FE0-A4F5-CB08AEC84517 Q33752182-D0F4B456-1B83-4B61-B1E1-2087E0251B37 Q33754477-0392A340-FCFA-4AE2-B51D-8E4916004CD3 Q34257657-FE31A6BE-4FAB-4201-8EFC-260DD253EF66 Q34302117-F904FA8E-E11B-4A6A-80D2-0CC75AF35C54 Q34450365-CA341BFB-5A3D-4C60-9D55-D7107C882B8A Q34699548-A5B747D7-9E70-4326-BFF8-D8565325182E Q35024541-0FE9E32C-3AE8-41CF-8940-56EB6A89D0A9 Q35091715-EBC861D2-FB45-468E-8078-2C43C20A4432 Q35107079-459E4AFD-5BE5-48D9-8592-B9AAA4EFD729 Q35107098-47EDF089-61A5-4CB5-B5AE-CBB55A81E15D Q35532746-2D87603D-F162-492E-8A8F-CCB79C72D45D Q35566987-913FFADC-C6A6-4CF7-BDAB-E3346103D125 Q35567223-FC4CDD8C-C8EE-429B-B164-954859FB79C7 Q36040066-0EED6B41-BE3B-4C60-8E46-C19209037089 Q36349735-092A40CF-820B-4704-B5AC-20AB44D42C1E Q36715005-55D18D5F-2A2D-4DD6-9C72-4C713168213C

P2860

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

http://www.wikidata.org/entity/Q51984024

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Treatment effects of drotrecog ...... ted intravascular coagulation.

@en

Treatment effects of drotrecogin alfa

@nl

type

label

Treatment effects of drotrecog ...... ted intravascular coagulation.

@en

Treatment effects of drotrecogin alfa

@nl

prefLabel

Treatment effects of drotrecog ...... ted intravascular coagulation.

@en

Treatment effects of drotrecogin alfa

@nl

P1433

Q51984024-E0CDDE7C-093C-4C85-A9E4-45B09BD50778

P1476

Q51984024-10BDC73D-9402-44DA-AF68-8EAEF6A6402B

P2093

Q51984024-2FA6281A-893F-4D01-97CE-E753D2468735

Q51984024-36AB5DE1-ADBA-464D-BBAF-CD014C65D7CB

Q51984024-4DE5EC2B-38A7-4BC6-9D04-9DF750C823E7

Q51984024-70252045-6D70-402B-BB7D-A0034C91338C

Q51984024-71CA5A51-C368-43DD-ACEB-866C63857485

Q51984024-8EBF506B-B5A3-4F19-9891-EF51B578574D

Q51984024-9E3A5527-527B-436B-905B-C2DA8B4B0CA2

Q51984024-B7CED785-8D9B-4103-9C92-DE245E2DA4FD

P2860

Q51984024-05AA58FC-505F-4973-B227-C18215793E87

Q51984024-0A71478A-0977-42D1-B906-4A2E46E87AEB

Q51984024-54CE2CFE-79EA-450C-8C61-12DEEE7A6BEC

Q51984024-6DC6BABA-9B40-48D0-BB26-295B4A1B5D47

Q51984024-71A10BBF-8150-4A00-AC5C-B372F9967632

Q51984024-A627AB7C-183D-49D5-9DE7-AD4CFC1993DB

Q51984024-CF108AB3-A676-4BF3-B71E-21826E0FC750

P304

Q51984024-2E637E01-C551-4748-AE57-0C3D61610F41

P31

Q51984024-19C8AB14-A28B-419D-8A6C-90B4C1D777A1

P356

Q51984024-16401E65-4E77-46EF-92CC-43A2768C7FE5

P433

Q51984024-88CEAA10-CDA5-478E-8E30-D3A13629F33E

P478

Q51984024-BF32C6F4-AE8F-4237-A2B3-83DDA52D06A6

P577

Q51984024-E46CAB44-234B-4AFE-ADF2-67E864266367

P5875

Q51984024-695DDDC8-813F-44F1-A4C5-E74F0A045C59

P698

Q51984024-1259B09A-F699-44C7-8430-CA1DEF4C4707

P356

J.1538-7836.2004.00955.X

P1433

Journal of Thrombosis and Haemostasis

P1476

Treatment effects of drotrecog ...... ted intravascular coagulation.

@en

P2093

B Basson

http://www.w3.org/2001/XMLSchema#string

D E Joyce

http://www.w3.org/2001/XMLSchema#string

D P Sundin

http://www.w3.org/2001/XMLSchema#string

J T Brandt

http://www.w3.org/2001/XMLSchema#string

J-F Dhainaut

http://www.w3.org/2001/XMLSchema#string

M Levi

http://www.w3.org/2001/XMLSchema#string

S B Yan

http://www.w3.org/2001/XMLSchema#string

V Pettilä

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of recombinant human activated protein C for severe sepsis

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

Time course of platelet counts in critically ill patients.

Disseminated intravascular coagulation in sepsis.

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.

Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.

High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.

P304

1924-1933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1538-7836.2004.00955.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8177325

http://www.w3.org/2001/XMLSchema#string

P698

15550023

http://www.w3.org/2001/XMLSchema#string